DAX+0,39 % EUR/USD+0,02 % Gold+0,14 % Öl (Brent)+0,02 %
30,25
 
EUR
20.01.20 Lang & Schwarz
-0,49 %
-0,15 EUR
Geldkurs 20.01.20
29,80 EUR
164 Stk.
Briefkurs 20.01.20
30,70 EUR
164 Stk.

Nachrichten zu Idorsia

Neurocrine Biosciences owns option to exclusively license ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of epilepsyIdorsia to receive $45 million upfront upon exercise of the option and up to $365 million in …

Wertpapier:

Neurocrine Biosciences owns option to exclusively license ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of epilepsyIdorsia to receive $45 million upfront upon exercise of the option and up to $365 million in …

Wertpapier:

weitere Idorsia Nachrichten

ZeitTitel
05.12.19
05.12.19
14.11.19
11.11.19
25.10.19
22.10.19
03.05.19
03.05.19
18.04.19
18.04.19
29.03.19
29.03.19
07.02.19
07.02.19
05.02.19
05.02.19
31.01.19
31.01.19